Rheumatoid Arthritis News

EULAR has launched RheumaFacts, a novel resource for local and national data regarding rheumatic and musculoskeletal diseases in Europe, according to a presenter at the EULAR 2023 Congress.

Managing comorbidities is critical to minimizing deaths in patients with rheumatic and musculoskeletal diseases, according to data presented at EULAR 2023 Congress.

Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.

For the prevention of rheumatoid arthritis to become feasible, it may be necessary to intervene as soon as possible in the pre-RA course, although the specific timing remains unclear, according to a speaker at the EULAR 2023 Congress.

An open-access training video originally produced for a study into remote monitoring among patients with rheumatoid arthritis unexpectedly attracted more than 40,000 views within 10 months, alongside positive reviews, according to data.

The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.

Properly managing cardiovascular disease in patients with immune-mediated inflammatory diseases requires following guidelines and inter-specialty collaboration, according to a speaker at the Biologic Therapies Summit.

The FDA has given the green light to a new autoinjector option for the interchangeable adalimumab biosimilar Cyltezo, just weeks ahead of its scheduled debut in the United States, according to a press release from the manufacturer.

The slow march toward precision medicine in rheumatoid arthritis features increased use of serum biomarkers and novel approaches to biopsy, but “a ton of hurdles” remain, according to a presenter at the Biologic Therapies Summit.

The pipeline of Janus kinase inhibitors is robust even as researchers struggle to fully understand how they work, according to a presenter at the 2023 Biologic Therapies Summit.